Luigi Annunziata

Dr. Luigi Annunziata


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SMSaponaro Mariarosaria
Saponaro Mariarosaria
LALuigi Annunziata
Luigi Annunziata
ATAntonella Turla
Antonella Turla
IVIlaria Viganò
Ilaria Viganò
Michelino De LaurentiisMichelino De Laurentiis
Michelino De Laurentiis
GAGrazia Arpino
Grazia Arpino
In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice.

30 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GRGerardo Rosati
Gerardo Rosati
MMMichele Montrone
Michele Montrone
CPCarmen Pacilio
Carmen Pacilio
ACAlfredo Colombo
Alfredo Colombo
GCGiuseppe Cicero
Giuseppe Cicero
DBDomenico Bilancia
Domenico Bilancia
Although colorectal cancer is increasingly being diagnosed in older patients, their number is largely underrepresented in phase II or III clinical trials. Consequently, guidelines and the SIOG recommendations are not sufficiently clear regarding the treatment of these patients, particularly when chemotherapy is combined with monoclonal antibodies (bevacizumab, cetuximab, and panitumumab). Targeted therapy based on the use of anti-epidermal growth factor receptors (EGFRs) is conditioned by the potential for increased toxicity, making it more difficult to treat an older, rat sarcoma virus (RAS) and B rapidly accelerated fibrosarcoma (BRAF) wild-type patient. In light of a more detailed characterization of the older population, modernly differentiable between fit, vulnerable, or frail patients on the basis of the comprehensive geriatric assessment, and of the analysis of more recent studies, this review fully collects data from the literature, differentiating the results on functional status patients.